Given the distinct influence of ERO1a inhibition on the hypoxic tumor secretome and the greater impact of IDO1 inhibition on myeloid signaling, the combined effect of ERO1a and IDO1 inhibition at the same single treatment concentration was investigated for their immune-related biological pathways. Here, IDO1 is linked to neoplasm.